1. 105 HIGH RESPONSE RATE FOR AZACITIDINE-LENALIDOMIDE (VI-LEN) COMBINATION IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) - VILEN-01 PROTOCOL UPDATE. (April 2015) Authors: Mittelman, M.; Filanovsky, K.; Ofran, Y.; Raanani, P.; Braester, A.; Goldshmidt, N.; Kirgner, I.; Herishanu, Y.; Perry, C.; Oster, H.S. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 194 ACUTE FIBRINOUS ORGANIZING PNEUMONIA AS A PARA NEOPLASTIC PHENOMENA IN A HIGH RISK MYELODYSPLASTIC SYNDROME PATIENT RESOLVING WITH AZACITIDINE THERAPY. Issue 1 (April 2015) Authors: Ofran, Y.; Yigla, M. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis. (February 2020) Authors: Beyar-Katz, O.; Bitterman, R.; Zuckerman, T.; Ofran, Y.; Yahav, D.; Paul, M. Journal: Clinical microbiology and infection Issue: Volume 26:Number 2(2020) Page Start: 189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P578: GILTERITINIB FOR RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA A REAL-WORLD, MULTI-CENTER, MATCHED ANALYSIS. (23rd June 2022) Authors: Shimony, S.; Canaani, J.; Kugler, E.; Nachmias, B.; Ram, R.; Frisch, A.; Ganzel, C.; Vainstein, V.; Moshe, Y.; Aumann, S.; Yeshurun, M.; Ofran, Y.; Raanani, P.; Wolach, O. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 477 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P585: VENETOCLAX IN COMBINATION WITH INTENSIVE TREATMENT PROTOCOLS FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA – A MULTICENTER REAL-WORLD ANALYSIS. (23rd June 2022) Authors: Wolach, O.; Frisch, A.; Shargian, L.; Yeshurun, M.; Apel, A.; Vainstein, V.; Moshe, Y.; Shimony, S.; Amit, O.; Bar On, Y.; Ofran, Y.; Raanani, P.; Nachmias, B.; Ram, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1). (23rd June 2022) Authors: DeZern, A.; Marconi, G.; Deeren, D.; Diez Campelo, M.; Lübbert, M.; Krishnamurthy, P.; Nagy, Z.; Basak, G.; Jonášová, A.; Morozova, E.; Geissler, K.; Ofran, Y.; Kelley, H.; Volkert, A.; Baker, K.; Kang-Fortner, Q.; Hodgson, G.; Madigan, C.; Roth, D. A.; Kelly, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1800 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS. (May 2023) Authors: Dezern, A.; Fenaux, P.; Deeren, D.; Campelo, M.; Lübbert, M.; Krishnamurthy, P.; Nagy, Z.; Basak, G.; Jonasova, A.; Geissler, K.; Ofran, Y.; Klimek, V.; Volkert, A.; Chisholm, J.; Hu, B.; Hodgson, G.; Roth, D.A.; Kelly, M.; Marconi, G. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗